Immune Evasion Mechanisms and Advances in Virus-Related Blood Cancer Treatments
Overview
Viral infections such as EBV, KSHV, HIV, HBV, HCV, and HTLV-1 play critical roles in the development and progression of various hematological malignancies by enabling immune escape and promoting tumor growth. Recent therapeutic advances focus on targeting viral proteins, immune checkpoints, and virus-specific immune responses to overcome treatment resistance and improve patient outcomes.
Background
Virus-associated hematological malignancies arise through complex interactions involving viral infection, latency, and oncogenic protein expression that disrupt normal immune surveillance. EBV is notably linked to several lymphomas, while HIV-induced immunosuppression facilitates co-infections that increase lymphoma risk. Other viruses like KSHV and HTLV-1 contribute to distinct lymphoproliferative disorders via latent and lytic infection cycles. Understanding these mechanisms is essential for developing precision therapies beyond traditional chemotherapy.
Data Highlights
Key viral proteins and pathways implicated include EBV's LMP1 activating NF-κB and JAK-STAT, EBNA2 hijacking NOTCH and c-Myc pathways, KSHV's LANA maintaining latency and vIL-6 activating JAK-STAT, and HCV NS3/4A modulating BCR signaling. HIV causes CD4+ T cell depletion leading to immune collapse and increased lymphoma susceptibility. These molecular insights underpin novel therapeutic strategies targeting viral oncogenesis and immune evasion.
Key Findings
EBV establishes latent infection in B cells, promoting immune escape and lymphoma development through LMP1 and EBNA2-mediated signaling.
HIV infection impairs CD4+ T cell function, increasing susceptibility to oncogenic viruses and elevating risks of DLBCL and Burkitt lymphoma.
KSHV maintains latency via LANA and promotes tumorigenesis through vIL-6-induced JAK-STAT activation, contributing to PEL and MCD.
HBV and HCV disrupt immune responses and promote malignant transformation through viral protein interactions affecting signaling pathways such as miR-34a dysregulation and BCR signaling.
HTLV-1 infection triggers T cell transformation and immunosuppression leading to adult T-cell leukemia/lymphoma (ATLL).
Novel therapies including immune checkpoint inhibitors, virus-specific T-cell therapy, CAR-T, oncolytic viruses, and therapeutic vaccines are being explored to target virus-driven immune escape mechanisms.
Clinical Implications
Clinicians should consider viral infection status and associated immune dysfunction when diagnosing and treating hematological malignancies. Monitoring viral load, especially EBV, is important for prognosis and therapeutic decisions. Integrating antiviral therapies with novel immunotherapies targeting viral proteins and immune checkpoints may enhance treatment efficacy and reduce toxicity.
Conclusion
Virus-driven immune evasion is central to the pathogenesis of multiple blood cancers, necessitating targeted therapeutic approaches. Advances in understanding viral oncogenesis and immune interactions provide a foundation for precision medicine strategies to improve outcomes in virus-associated hematological malignancies.
References
Comprehensive review on virus-associated hematological malignancies and therapies
